Decreasing tropomyosin phosphorylation rescues tropomyosin-induced familial hypertrophic cardiomyopathy
| Autor: | Emily M. Schulz, Shamim A. K. Chowdhury, R. John Solaro, Beata M. Wolska, Hajer N. Sheikh, Tanganyika Wilder, David F. Wieczorek |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cardiac function curve
Genetically modified mouse medicine.medical_specialty Myofilament Transgene Immunoblotting Context (language use) Mice Transgenic macromolecular substances Tropomyosin Biology Biochemistry Mice Myofibrils Internal medicine medicine Cardiomyopathy Hypertrophic Familial Animals Myocytes Cardiac Calcium Signaling Phosphorylation Molecular Biology Ultrasonography Myocardium fungi food and beverages Cell Biology Molecular biology Phospholamban Endocrinology Gene Expression Regulation Heart Function Tests Calcium Mutant Proteins |
| Zdroj: | The Journal of biological chemistry. 288(40) |
| ISSN: | 1083-351X |
| Popis: | Background: Increased calcium uptake can rescue congenital cardiomyopathies. Results: Decreasing tropomyosin phosphorylation increases phospholamban phosphorylation and improves cardiac function and morphology in a cardiomyopathic mouse. Conclusion: Changing tropomyosin phosphorylation can influence calcium handling to adverse cardiac remodeling. Significance: This is the first report that altering tropomyosin phosphorylation can rescue a cardiomyopathic phenotype. Studies indicate that tropomyosin (Tm) phosphorylation status varies in different mouse models of cardiac disease. Investigation of basal and acute cardiac function utilizing a mouse model expressing an α-Tm protein that cannot be phosphorylated (S283A) shows a compensated hypertrophic phenotype with significant increases in SERCA2a expression and phosphorylation of phospholamban Ser-16 (Schulz, E. M., Correll, R. N., Sheikh, H. N., Lofrano-Alves, M. S., Engel, P. L., Newman, G., Schultz Jel, J., Molkentin, J. D., Wolska, B. M., Solaro, R. J., and Wieczorek, D. F. (2012) J. Biol. Chem. 287, 44478–44489). With these results, we hypothesized that decreasing α-Tm phosphorylation may be beneficial in the context of a chronic, intrinsic stressor. To test this hypothesis, we utilized the familial hypertrophic cardiomyopathy (FHC) α-Tm E180G model (Prabhakar, R., Boivin, G. P., Grupp, I. L., Hoit, B., Arteaga, G., Solaro, R. J., and Wieczorek, D. F. (2001) J. Mol. Cell. Cardiol. 33, 1815–1828). These FHC hearts are characterized by increased heart:body weight ratios, fibrosis, increased myofilament Ca2+ sensitivity, and contractile defects. The FHC mice die by 6–8 months of age. We generated mice expressing both the E180G and S283A mutations and found that the hypertrophic phenotype was rescued in the α-Tm E180G/S283A double mutant transgenic animals; these mice exhibited no signs of cardiac hypertrophy and displayed improved cardiac function. These double mutant transgenic hearts showed increased phosphorylation of phospholamban Ser-16 and Thr-17 compared with the α-Tm E180G mice. This is the first study to demonstrate that decreasing phosphorylation of tropomyosin can rescue a hypertrophic cardiomyopathic phenotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|